StockData

Ocugen vs Taysha Gene Therapies

OCGN and TSHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OCGN and TSHA compare

Taysha Gene Therapies is the larger company, worth 5.0 times as much as Ocugen ($1.3B against $262M).

Taysha Gene Therapies scores higher on the StockData Score (5 against 1 for Ocugen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOCGNTSHA
Size and price
Market cap$262M$1.3B
Share price$0.773$4.06
Change, 1 year−37.7%1.2%
Change, 5 years−88.0%−68.0%
Beta (5Y)−0.192.78
Employees11699
StockData Score
Total score15 (better)
Valuation score00
Growth score11
Performance score01 (better)
Health score03 (better)
Dividend score00
Valuation
P/S–241×
P/B–3.4×
FCF yield−23.3%−10.0% (better)
Growth
Revenue growth (TTM)–−32.3%
Revenue growth, 5Y average152%–
Profitability
Operating margin–−2792%
Net margin–−2728%
FCF margin–−2417%
Return on equity–−47.1%
Financial health
Debt / equity–0.13
Interest coverage−8.2× (better)−3646.6×
Current ratio0.8017.76 (better)
Altman Z-score−6.067.21 (better)
Piotroski F-score05 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions42.8%91.9%
Held by insiders2.4%10.7%
Insider net buying, 12 months−$1.1M (better)−$6.1M
Short interest, % of float32.5%18.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.